Home » Stocks » AXNX

Axonics Modulation Technologies, Inc. (AXNX)

Stock Price: $50.76 USD -0.90 (-1.73%)
Updated Jan 20, 2021 3:15 PM EST - Market open
Market Cap 2.06B
Revenue (ttm) 86.70M
Net Income (ttm) -66.32M
Shares Out 38.83M
EPS (ttm) -1.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $50.76
Previous Close $51.65
Change ($) -0.90
Change (%) -1.73%
Day's Open 51.85
Day's Range 50.72 - 52.50
Day's Volume 193,225
52-Week Range 16.44 - 52.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 month ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Business Wire - 2 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Business Wire - 2 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Seeking Alpha - 2 months ago

Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen On Q3 2020 Results - Quick Earnings Call Transcript

Zacks Investment Research - 2 months ago

Axonics (AXNX) delivered earnings and revenue surprises of 53.85% and 60.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Business Wire - 2 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Zacks Investment Research - 2 months ago

Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 3 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Business Wire - 3 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Business Wire - 3 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Business Wire - 3 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Zacks Investment Research - 3 months ago

Axonics (AXNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Investors Business Daily - 3 months ago

Down Session Has Bullish Undertones

Stock indexes didn’t give up much ground Tuesday after strong gains Monday.

Other stocks mentioned: BYND, ENTG
Business Wire - 3 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Business Wire - 3 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Business Wire - 4 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

Business Wire - 4 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

Business Wire - 4 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

Business Wire - 4 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

Business Wire - 4 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

Seeking Alpha - 5 months ago

Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

Business Wire - 5 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

Business Wire - 6 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

Business Wire - 6 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Business Wire - 6 months ago

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...

Benzinga - 7 months ago

Axonics Modulation Technologies Inc (NASDAQ: AXNX) shares are trading higher on Wednesday.

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Axonics Modulation Technologies.

Seeking Alpha - 8 months ago

Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Axonics (AXNX) delivered earnings and revenue surprises of 23.21% and 87.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 10 months ago

Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Axonics (AXNX) delivered earnings and revenue surprises of -17.19% and -0.54%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 1 year ago

A sneak peek at its fourth-quarter financial performance is fueling investors' optimism.

Seeking Alpha - 1 year ago

Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Axonics (AXNX) delivered earnings and revenue surprises of -21.92% and -9.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 1 year ago

Shares jump after the medical device maker announces that it has secured an important regulatory win.

GuruFocus - 1 year ago

There may be a good investment opportunity in an Irvine, California-based startup that is challenging medical technology giant Medtronic (NYSE:MDT) with what appears to be a superior device to...

Zacks Investment Research - 1 year ago

Axonics (AXNX) expects to improve performance on the positive outcome of the study.

GuruFocus - 1 year ago

CEO of Axonics Modulation Technologies Inc (30-Year Financial, Insider Trades) Raymond W Cohen (insider trades) bought 3,500 shares of AXNX on 08/06/2019 at an average price of $30.41 a share.

Seeking Alpha - 1 year ago

Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q2 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

This medical device stock has been on a tear since the company's Halloween 2018 IPO.

Seeking Alpha - 1 year ago

Axonics Modulation Technologies' (AXNX) CEO Ray Cohen on Q1 2019 Results - Earnings Call Transcript

About AXNX

Axonics Modulation Technologies, a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems in the United States and internationally. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence, and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication ... [Read more...]

Industry
Medical Devices
CEO
Raymond Cohen
Employees
302
Stock Exchange
NASDAQ
Ticker Symbol
AXNX
Full Company Profile

Financial Performance

In 2019, AXNX's revenue was $13.82 million, an increase of 1,854.74% compared to the previous year's $707,000. Losses were -$79.94 million, 146.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for AXNX stock is "Strong Buy." The 12-month stock price forecast is 62.33, which is an increase of 22.81% from the latest price.

Price Target
$62.33
(22.81% upside)
Analyst Consensus: Strong Buy